CHO

Towards Genome Engineering in Chinese Hamster Ovary Cells

Archived Webinar
Dec 14, 2010
Worth over $30 billion, therapeutic proteins, produced by recombinant mammalian cells, have been the fastest growing class of medicines in industrialized nations. Their importance in the health industry in the next decade will be ever greater as their reach expands, improving the quality of life of...

Recombinant Protein Therapeutics from CHO Cells -- 20 Years and Counting

October
2007
SBE Special Section
Dr. Wei-Shou Hu, Karthik P. Jayapal, Katie F Wlaschin, Wei-Shou Hu and Miranda G. S. Yap
The CHO cell is at its height of technological prominence thanks to its adaptability to various culture conditions and plasticity in the context of genetic alterations. With further research, the application ofCell Culture Strategies based on...

Singapore: An Emerging Leader in Biomedical Sciences

October
2007
SBE Special Section
Niki S. C. Wong, Miranda G. S. Yap
With a heavy investment in biomedical research— particularly the $330 million to build Biopolis in 2003— Singapore is seeing the fruits of its labor blossom.

Industry and SBE News

October
2007
SBE Special Section
Dr. George Georgiou to Receive SBE's James E. Bailey Award; Averting an Epidemic— Novel Device Detects Avian Flu Virus in Less than Half an Hour; Cell-Free Protein Sythesis Comes of Age; Genetically Engineering Microorganisms into Pharmaceutical...

Deciphering the Mechanisms of Therapeutic Protein Production

October
2007
SBE Special Section
Daniel W. Allison, Christoph L. Bausch, Trissa Borgschulte, Matthew V. Caple, Kevin J. Kayser
Demand for therapeutic recombinant proteins will eventually exceed current production capabilities. This is a major driver in further understanding Chinese Hamster Ovary (CHO) cell biology, which is the cell line of choice for producing these...
Subscribe to CHO